TY  - JOUR
A1  - Wiegering, Armin
A1  - Pfann, Christina
A1  - Uthe, Friedrich Wilhelm
A1  - Otto, Christoph
A1  - Rycak, Lukas
A1  - Mäder, Uwe
A1  - Gasser, Martin
A1  - Waaga-Gasser, Anna-Maria
A1  - Eilers, Martin
A1  - Germer, Christoph-Thomas
T1  - CIP2A Influences Survival in Colon Cancer and Is Critical for Maintaining Myc Expression
JF  - PLoS ONE
N2  - The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor that stabilises the c-Myc protein. CIP2A is overexpressed in several tumours, and expression levels are an independent marker for long-term outcome. To determine whether CIP2A expression is elevated in colon cancer and whether it might serve as a prognostic marker for survival, we analysed CIP2A mRNA expression by real-time PCR in 104 colon cancer samples. CIP2A mRNA was overexpressed in colon cancer samples and CIP2A expression levels correlated significantly with tumour stage. We found that CIP2A serves as an independent prognostic marker for disease-free and overall survival. Further, we investigated CIP2A-dependent effects on levels of c-Myc, Akt and on cell proliferation in three colon cancer cell lines by silencing CIP2A using small interfering (si) and short hairpin (sh) RNAs. Depletion of CIP2A substantially inhibited growth of colon cell lines and reduced c-Myc levels without affecting expression or function of the upstream regulatory kinase, Akt. Expression of CIP2A was found to be dependent on MAPK activity, linking elevated c-Myc expression to deregulated signal transduction in colon cancer.
KW  - caco-2 cells
KW  - carcinomas
KW  - colon
KW  - colorectal cancer
KW  - MAPK signaling cascades
KW  - metastasis
KW  - protein expression
KW  - small interferring RNA
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-97252
ER  - 
TY  - JOUR
A1  - Wilhelm, Martin
A1  - Smetak, Manfred
A1  - Schaefer-Eckart, Kerstin
A1  - Kimmel, Brigitte
A1  - Birkmann, Josef
A1  - Einsele, Hermann
A1  - Kunzmann, Volker
T1  - Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells
JF  - Journal of Translational Medicine
N2  - Background: The primary aim of this pilot study was to determine the feasibility and safety of an adoptive transfer and in vivo expansion of human haploidentical gamma delta T lymphocytes. 
Methods: Patients with advanced haematological malignancies who are not eligible for allogeneic transplantation received peripheral blood mononuclear cells from half-matched family donors. For that, a single unstimulated leukapheresis product was incubated with both the anti-CD4 and anti-CD8 antibodies conjugated to paramagnetic particles. The depletion procedure was performed on a fully automated CliniMACS (R) device according to the manufacturer's instructions. On average, patients received 2.17 x 10(6)/kg (range 0.9-3.48) γδ T cells with <1% CD4-or CD8-positive cells remaining in the product. All patients received prior lymphopenia-inducing chemotherapy (fludarabine 20-25 mg/m(2) day -6 until day -2 and cyclophosphamide 30-60 mg/kg day -6 and -5) and were treated with 4 mg zoledronate on day 0 and 1.0x10(6) IU/m(2) IL-2 on day +1 until day +6 for the induction of gamma delta T cell proliferation in vivo. 
Results: This resulted in a marked in vivo expansion of donor γδ T cells and, to a lower extent, natural killer cells and double-negative αβ T cells (mean 68-fold, eight-fold, and eight-fold, respectively). Proliferation peaked by around day +8 and donor cells persisted up to 28 days. Although refractory to all prior therapies, three out of four patients achieved a complete remission, which lasted for 8 months in a patient with plasma cell leukaemia. One patient died from an infection 6 weeks after treatment. 
Conclusion: This pilot study shows that adoptive transfer and in vivo expansion of haploidentical γδ T lymphocytes is feasible and suggests a potential role of these cells in the treatment of haematological diseases.
KW  - NK cells
KW  - in vivo cell expansion
KW  - haploidentical γδ T lymphocytes
KW  - adoptive transfer
KW  - CD4(+)
KW  - innate immunity
KW  - stimulation
KW  - acute myeloid-leukemia
KW  - immunotherapy
KW  - cancer
KW  - infusion
KW  - Interleukin-2
KW  - biophosphonate
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117290
VL  - 12
IS  - 45
ER  -